摘要
目的观察R-CHOP方案治疗复发、难治弥漫大B细胞淋巴瘤（DLBCL）的临床疗效及患者不良反应。方法选择30例经病理证实为CD。阳性的DLBCL患者，前期常规方案化疗（不含利妥昔单抗）2～6个疗程后评估为复发或难治患者，其中复发患者16例，难治患者14例。应用R—CHOP方案治疗4～6个周期，每个周期21d。所有淋巴瘤患者均为Ⅲ～Ⅳ期，搜集治疗前后相关临床资料，采用回顾性分析方法，将R—CHOP方案疗效与文献及自身对照比较，评价其疗效及不良反应。结果全组30例患者均可评价疗效，完全缓解15例，部分缓解10例，稳定3例，进展2例，完全缓解率为50．0％（15／30），总有效率83．3％（25／30）。出现Ⅱ度白细胞减少3例，I度血小板降低1例，恶心等轻微的消化道反应2例。结论R-CHOP方案对复发、难治DLBCL仍有良好的治疗效果，完全缓解率与总有效率明显优于常规二线化疗方案。接受R-CHOP方案治疗患者不良反应轻微，与常规化疗方案无显著区别，患者耐受良好。
Objective To evaluate the clinical efficacy and toxicity of rituximab combined with CHOP （R-CHOP） in the treatment of relapsed or refractory diffuse large B cell lymphoma （DLBCL）. Methods 30 patients were enrolled. All patients, pathologically confirmed to be CD20 positive DLBCL （all in stages IU-IV ）, were relapsed or refractory after received 2-6 cycles of chemotherapy. Then all of them received R-CHOP schedule for 4 to 6 cycles, each cycle was 21 days. Clinical data before and after R-CHOP were collected. A retrospective analysis of the R-CHOP therapy, either compared to the literature or self-control was performed to evaluate the efficacy and toxicity. Results All the 30 patients were evaluable, induding 15 cases were complete remission （CR）, 10 cases were partial remission （PR）, 3 cases were stable disease （SD）, and 2 cases were progressed disease （PD）. The CR rate was 50.0 % （15/30）, the total response rate （RR） was 83.3 % （25/30）. All patients were well tolerated to the therapy. Only 3 cases were Ⅱ degree neutropenia, 1 case was I degree thrombocytopenia, and 2 cases suffered nausea and other mild gastrointestinal discomfort. Conclusions R-CHOP regimen could also achieve good response for relapsed or refractory DLBCL significantly. The commorl adverse effects of rituximab were mild. All the patients were well tolerated.
出处
《白血病．淋巴瘤》
CAS
2012年第10期601-603,共3页
Journal of Leukemia & Lymphoma
